MiMedx Group Inc (MDXG)
7.325
+0.20
(+2.73%)
USD |
NASDAQ |
May 07, 13:33
MiMedx Group Revenue (Quarterly): 84.71M for March 31, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 84.71M |
December 31, 2023 | 86.83M |
September 30, 2023 | 81.71M |
June 30, 2023 | 81.26M |
March 31, 2023 | 71.68M |
December 31, 2022 | 74.38M |
September 30, 2022 | 67.69M |
June 30, 2022 | 66.88M |
March 31, 2022 | 58.89M |
December 31, 2021 | 50.81M |
September 30, 2021 | 63.07M |
June 30, 2021 | 68.16M |
March 31, 2021 | 59.97M |
December 31, 2020 | 68.55M |
September 30, 2020 | 64.30M |
June 30, 2020 | 53.65M |
March 31, 2020 | 61.74M |
December 31, 2019 | 76.40M |
September 30, 2019 | 88.86M |
June 30, 2019 | 67.44M |
March 31, 2019 | 66.56M |
December 31, 2018 | 92.59M |
September 30, 2018 | 86.96M |
June 30, 2018 | 95.42M |
March 31, 2018 | 84.15M |
Date | Value |
---|---|
December 31, 2017 | 87.55M |
September 30, 2017 | 84.57M |
June 30, 2017 | 76.41M |
March 31, 2017 | 72.61M |
December 31, 2016 | 46.57M |
September 30, 2016 | 64.43M |
June 30, 2016 | 57.34M |
March 31, 2016 | 53.37M |
December 31, 2015 | 51.84M |
September 30, 2015 | 49.02M |
June 30, 2015 | 45.68M |
March 31, 2015 | 40.77M |
December 31, 2014 | 39.57M |
September 30, 2014 | 33.52M |
June 30, 2014 | 25.57M |
March 31, 2014 | 19.56M |
December 31, 2013 | 17.99M |
September 30, 2013 | 16.12M |
June 30, 2013 | 13.51M |
March 31, 2013 | 11.56M |
December 31, 2012 | 10.51M |
September 30, 2012 | 7.954M |
June 30, 2012 | 4.884M |
March 31, 2012 | 3.706M |
December 31, 2011 | 2.636M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
50.81M
Minimum
Dec 2021
88.86M
Maximum
Sep 2019
69.85M
Average
67.93M
Median
Revenue (Quarterly) Benchmarks
TELA Bio Inc | 17.00M |
Amylyx Pharmaceuticals Inc | 108.45M |
CEL-SCI Corp | -- |
AIM ImmunoTech Inc | 0.065M |
IGC Pharma Inc | 0.204M |
Revenue (Quarterly) Related Metrics
Net Income (Quarterly) | 9.261M |
Total Expenses (Quarterly) | 71.46M |
EPS Diluted (Quarterly) | 0.06 |
Enterprise Value | 1.023B |
Gross Profit Margin (Quarterly) | 84.67% |
Profit Margin (Quarterly) | 10.93% |
Earnings Yield | 6.83% |
Operating Earnings Yield | 5.52% |
Normalized Earnings Yield | 6.899 |